JP2008535853A - 癌関連遺伝子 - Google Patents
癌関連遺伝子 Download PDFInfo
- Publication number
- JP2008535853A JP2008535853A JP2008505600A JP2008505600A JP2008535853A JP 2008535853 A JP2008535853 A JP 2008535853A JP 2008505600 A JP2008505600 A JP 2008505600A JP 2008505600 A JP2008505600 A JP 2008505600A JP 2008535853 A JP2008535853 A JP 2008535853A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- gene
- antibody
- expression
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 459
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 367
- 201000011510 cancer Diseases 0.000 title claims abstract description 231
- 230000014509 gene expression Effects 0.000 claims abstract description 142
- 238000000034 method Methods 0.000 claims abstract description 132
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 79
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 58
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 56
- 206010046766 uterine cancer Diseases 0.000 claims abstract description 47
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 42
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 37
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 35
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 33
- 208000002495 Uterine Neoplasms Diseases 0.000 claims abstract description 33
- 208000008839 Kidney Neoplasms Diseases 0.000 claims abstract description 32
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 31
- 208000000453 Skin Neoplasms Diseases 0.000 claims abstract description 31
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 31
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 27
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 27
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 27
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 26
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 25
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 25
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 25
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 24
- 201000005202 lung cancer Diseases 0.000 claims abstract description 24
- 201000007270 liver cancer Diseases 0.000 claims abstract description 22
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 22
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 22
- 201000000849 skin cancer Diseases 0.000 claims abstract description 21
- 206010038389 Renal cancer Diseases 0.000 claims abstract description 20
- 201000010982 kidney cancer Diseases 0.000 claims abstract description 20
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 18
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 16
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 16
- 206010005003 Bladder cancer Diseases 0.000 claims abstract description 11
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims abstract description 11
- 201000001441 melanoma Diseases 0.000 claims abstract description 11
- 201000005112 urinary bladder cancer Diseases 0.000 claims abstract description 11
- 108020004999 messenger RNA Proteins 0.000 claims description 184
- 229920001184 polypeptide Polymers 0.000 claims description 94
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 94
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 94
- 210000001519 tissue Anatomy 0.000 claims description 89
- 238000003745 diagnosis Methods 0.000 claims description 79
- -1 MET Proteins 0.000 claims description 76
- 210000004027 cell Anatomy 0.000 claims description 72
- 238000011282 treatment Methods 0.000 claims description 70
- 101001123448 Homo sapiens Prolactin receptor Proteins 0.000 claims description 49
- 102100029000 Prolactin receptor Human genes 0.000 claims description 49
- 101000638255 Homo sapiens Tumor necrosis factor ligand superfamily member 8 Proteins 0.000 claims description 47
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims description 47
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 41
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 40
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 40
- 101000899442 Homo sapiens Cadherin-23 Proteins 0.000 claims description 39
- 101000866287 Homo sapiens Excitatory amino acid transporter 2 Proteins 0.000 claims description 39
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 claims description 39
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims description 39
- 102000012980 SLC1A2 Human genes 0.000 claims description 39
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 39
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 claims description 39
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims description 39
- 102100022509 Cadherin-23 Human genes 0.000 claims description 38
- 101001077426 Homo sapiens Potassium voltage-gated channel subfamily H member 5 Proteins 0.000 claims description 38
- 102100026894 Lymphotoxin-beta Human genes 0.000 claims description 38
- 102100025071 Potassium voltage-gated channel subfamily H member 5 Human genes 0.000 claims description 38
- 102100031403 Beta-1,3-N-acetylglucosaminyltransferase lunatic fringe Human genes 0.000 claims description 37
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 claims description 37
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims description 37
- 101001130526 Homo sapiens Beta-1,3-N-acetylglucosaminyltransferase lunatic fringe Proteins 0.000 claims description 37
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 claims description 37
- 101001035232 Homo sapiens Integrin alpha-9 Proteins 0.000 claims description 37
- 101000764294 Homo sapiens Lymphotoxin-beta Proteins 0.000 claims description 37
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 claims description 37
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 37
- 108010072582 Matrilin Proteins Proteins 0.000 claims description 37
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 37
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims description 36
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 36
- 101000781955 Homo sapiens Proto-oncogene Wnt-1 Proteins 0.000 claims description 36
- 101000954762 Homo sapiens Proto-oncogene Wnt-3 Proteins 0.000 claims description 36
- 101000879840 Homo sapiens Serglycin Proteins 0.000 claims description 36
- 102100039903 Integrin alpha-9 Human genes 0.000 claims description 36
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims description 36
- 102100033669 Matrilin-2 Human genes 0.000 claims description 36
- 108010029755 Notch1 Receptor Proteins 0.000 claims description 36
- 108091006626 SLC12A7 Proteins 0.000 claims description 36
- 102100034252 Solute carrier family 12 member 7 Human genes 0.000 claims description 36
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 36
- 102000052547 Wnt-1 Human genes 0.000 claims description 36
- 102000052549 Wnt-3 Human genes 0.000 claims description 36
- 239000000523 sample Substances 0.000 claims description 36
- 108090000007 Carboxypeptidase M Proteins 0.000 claims description 35
- 102100031161 Collagen alpha-1(XIX) chain Human genes 0.000 claims description 35
- 101000940120 Homo sapiens Collagen alpha-1(XIX) chain Proteins 0.000 claims description 35
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 35
- 101000999079 Homo sapiens Radiation-inducible immediate-early gene IEX-1 Proteins 0.000 claims description 35
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 35
- 101000591201 Homo sapiens Receptor-type tyrosine-protein phosphatase kappa Proteins 0.000 claims description 35
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims description 35
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 35
- 102100034089 Receptor-type tyrosine-protein phosphatase kappa Human genes 0.000 claims description 35
- 102100029197 SLAM family member 6 Human genes 0.000 claims description 35
- 102000044880 Wnt3A Human genes 0.000 claims description 35
- 108700013515 Wnt3A Proteins 0.000 claims description 35
- 101150068520 wnt3a gene Proteins 0.000 claims description 35
- 102100034613 Annexin A2 Human genes 0.000 claims description 34
- 102100032936 Carboxypeptidase M Human genes 0.000 claims description 34
- 102100022640 Collagen alpha-1(XV) chain Human genes 0.000 claims description 34
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims description 34
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims description 34
- 101000924474 Homo sapiens Annexin A2 Proteins 0.000 claims description 34
- 101000899935 Homo sapiens Collagen alpha-1(XV) chain Proteins 0.000 claims description 34
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims description 34
- 101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 claims description 34
- 102100033467 L-selectin Human genes 0.000 claims description 34
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 claims description 34
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims description 33
- 101001010600 Homo sapiens Interleukin-12 subunit alpha Proteins 0.000 claims description 33
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 claims description 33
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 claims description 33
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 claims description 33
- 101150091468 IGSF8 gene Proteins 0.000 claims description 33
- 102100036489 Immunoglobulin superfamily member 8 Human genes 0.000 claims description 33
- 102100030698 Interleukin-12 subunit alpha Human genes 0.000 claims description 33
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 claims description 33
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 claims description 33
- 108091006529 SLC28A2 Proteins 0.000 claims description 33
- 108091006660 SLC9A9 Proteins 0.000 claims description 33
- 102100029967 Sodium/hydrogen exchanger 9 Human genes 0.000 claims description 33
- 102100021541 Sodium/nucleoside cotransporter 2 Human genes 0.000 claims description 33
- 102100035873 Tetraspanin-2 Human genes 0.000 claims description 33
- 101000585551 Equus caballus Pregnancy-associated glycoprotein Proteins 0.000 claims description 32
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 32
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 claims description 32
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 claims description 32
- 101000846336 Homo sapiens Ribitol-5-phosphate transferase FKTN Proteins 0.000 claims description 32
- 101000763003 Homo sapiens Two pore channel protein 1 Proteins 0.000 claims description 32
- 102100031754 Ribitol-5-phosphate transferase FKTN Human genes 0.000 claims description 32
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 32
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 claims description 32
- 102100021253 Antileukoproteinase Human genes 0.000 claims description 31
- 102100031510 Fibrillin-2 Human genes 0.000 claims description 31
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims description 31
- 101000615334 Homo sapiens Antileukoproteinase Proteins 0.000 claims description 31
- 101000846890 Homo sapiens Fibrillin-2 Proteins 0.000 claims description 31
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims description 31
- 101000879712 Streptomyces lividans Protease inhibitor Proteins 0.000 claims description 31
- 102100026736 Two pore channel protein 1 Human genes 0.000 claims description 31
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims description 30
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims description 30
- 101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 claims description 30
- 101000955355 Homo sapiens Xylosyltransferase 1 Proteins 0.000 claims description 30
- 102100038983 Xylosyltransferase 1 Human genes 0.000 claims description 30
- 150000007523 nucleic acids Chemical class 0.000 claims description 30
- 102100036411 Dermatopontin Human genes 0.000 claims description 29
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 claims description 29
- 101000929047 Homo sapiens Dermatopontin Proteins 0.000 claims description 29
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims description 29
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 29
- 102100032818 Integrin alpha-4 Human genes 0.000 claims description 29
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 29
- 108091006263 SLC4A8 Proteins 0.000 claims description 29
- 102000006633 Sodium-Bicarbonate Symporters Human genes 0.000 claims description 29
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 claims description 28
- 101001137975 Homo sapiens Leucyl-cystinyl aminopeptidase Proteins 0.000 claims description 28
- 101000825960 Homo sapiens R-spondin-3 Proteins 0.000 claims description 28
- 101000753197 Homo sapiens Sodium/potassium-transporting ATPase subunit alpha-2 Proteins 0.000 claims description 28
- 101000841325 Homo sapiens Urotensin-2 Proteins 0.000 claims description 28
- 102100020872 Leucyl-cystinyl aminopeptidase Human genes 0.000 claims description 28
- 102100022766 R-spondin-3 Human genes 0.000 claims description 28
- 102100021955 Sodium/potassium-transporting ATPase subunit alpha-2 Human genes 0.000 claims description 28
- 102100029097 Urotensin-2 Human genes 0.000 claims description 28
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims description 27
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims description 27
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 27
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 claims description 27
- 102100025246 Neurogenic locus notch homolog protein 2 Human genes 0.000 claims description 27
- 108010029751 Notch2 Receptor Proteins 0.000 claims description 27
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 27
- 101710151638 Tetraspanin-2 Proteins 0.000 claims description 27
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 claims description 27
- 108010079292 betaglycan Proteins 0.000 claims description 27
- 102000039446 nucleic acids Human genes 0.000 claims description 27
- 108020004707 nucleic acids Proteins 0.000 claims description 27
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 claims description 26
- 101001060280 Homo sapiens Fibroblast growth factor 3 Proteins 0.000 claims description 26
- 101000584583 Homo sapiens Receptor activity-modifying protein 1 Proteins 0.000 claims description 26
- 102100030697 Receptor activity-modifying protein 1 Human genes 0.000 claims description 26
- 239000012472 biological sample Substances 0.000 claims description 25
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 24
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 23
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 claims description 22
- 239000002246 antineoplastic agent Substances 0.000 claims description 22
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims description 21
- 102000040430 polynucleotide Human genes 0.000 claims description 21
- 108091033319 polynucleotide Proteins 0.000 claims description 21
- 239000002157 polynucleotide Substances 0.000 claims description 21
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 15
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 10
- 238000009739 binding Methods 0.000 claims description 10
- 239000013610 patient sample Substances 0.000 claims description 10
- 108091034117 Oligonucleotide Proteins 0.000 claims description 9
- 230000001093 anti-cancer Effects 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 210000000481 breast Anatomy 0.000 claims description 7
- 230000001413 cellular effect Effects 0.000 claims description 7
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- 101000658739 Homo sapiens Tetraspanin-2 Proteins 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 6
- 210000001072 colon Anatomy 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 230000001965 increasing effect Effects 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 239000012216 imaging agent Substances 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 239000002853 nucleic acid probe Substances 0.000 claims description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 230000004614 tumor growth Effects 0.000 claims description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 210000003443 bladder cell Anatomy 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 150000002484 inorganic compounds Chemical class 0.000 claims description 2
- 229910010272 inorganic material Inorganic materials 0.000 claims description 2
- 210000003292 kidney cell Anatomy 0.000 claims description 2
- 210000005229 liver cell Anatomy 0.000 claims description 2
- 210000005265 lung cell Anatomy 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 150000002894 organic compounds Chemical class 0.000 claims description 2
- 210000005267 prostate cell Anatomy 0.000 claims description 2
- 210000004927 skin cell Anatomy 0.000 claims description 2
- 102000001759 Notch1 Receptor Human genes 0.000 claims 12
- 102100030368 Phospholipid phosphatase-related protein type 4 Human genes 0.000 claims 12
- 101150015935 ATP2 gene Proteins 0.000 claims 1
- 101150033066 CD101 gene Proteins 0.000 claims 1
- 102100022516 Immunoglobulin superfamily member 2 Human genes 0.000 claims 1
- 102100032008 Solute carrier family 40 member 1 Human genes 0.000 claims 1
- 101710111423 Solute carrier family 40 member 1 Proteins 0.000 claims 1
- 101150026213 atpB gene Proteins 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 abstract description 27
- 230000002222 downregulating effect Effects 0.000 abstract 1
- 230000010354 integration Effects 0.000 description 80
- 235000018102 proteins Nutrition 0.000 description 75
- 241000714177 Murine leukemia virus Species 0.000 description 67
- 239000000047 product Substances 0.000 description 47
- 238000012353 t test Methods 0.000 description 30
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 24
- 102100037344 Serglycin Human genes 0.000 description 23
- 208000037141 Congenital muscular dystrophy, Fukuyama type Diseases 0.000 description 20
- 208000025855 muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4 Diseases 0.000 description 20
- 208000025421 tumor of uterus Diseases 0.000 description 19
- 230000002103 transcriptional effect Effects 0.000 description 18
- 102000052575 Proto-Oncogene Human genes 0.000 description 17
- 108700020978 Proto-Oncogene Proteins 0.000 description 17
- 208000019420 lymphoid neoplasm Diseases 0.000 description 17
- 230000035772 mutation Effects 0.000 description 16
- 208000023958 prostate neoplasm Diseases 0.000 description 16
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 12
- 208000037841 lung tumor Diseases 0.000 description 12
- 206010019695 Hepatic neoplasm Diseases 0.000 description 11
- 108700020796 Oncogene Proteins 0.000 description 10
- 230000002611 ovarian Effects 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 10
- 101000883798 Homo sapiens Probable ATP-dependent RNA helicase DDX53 Proteins 0.000 description 9
- 206010029098 Neoplasm skin Diseases 0.000 description 9
- 102100038236 Probable ATP-dependent RNA helicase DDX53 Human genes 0.000 description 9
- 238000000692 Student's t-test Methods 0.000 description 9
- 102000003675 cytokine receptors Human genes 0.000 description 9
- 108010057085 cytokine receptors Proteins 0.000 description 9
- 230000007423 decrease Effects 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 208000032839 leukemia Diseases 0.000 description 7
- 239000013615 primer Substances 0.000 description 7
- 230000001566 pro-viral effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 241001430294 unidentified retrovirus Species 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 108010078791 Carrier Proteins Proteins 0.000 description 5
- 206010061968 Gastric neoplasm Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 5
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000043276 Oncogene Human genes 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000036952 cancer formation Effects 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 101100409421 Plasmodium falciparum (isolate 3D7) Pfn gene Proteins 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108091006207 SLC-Transporter Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229940127121 immunoconjugate Drugs 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 2
- 201000010028 Acrocephalosyndactylia Diseases 0.000 description 2
- 101100310593 Candida albicans (strain SC5314 / ATCC MYA-2876) SOD4 gene Proteins 0.000 description 2
- 102100032363 Choline dehydrogenase, mitochondrial Human genes 0.000 description 2
- 101710181272 Choline dehydrogenase, mitochondrial Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 101710173431 L-carnitine dehydrogenase Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010070047 Notch Receptors Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 101710105116 Oxygen-dependent choline dehydrogenase Proteins 0.000 description 2
- 201000004014 Pfeiffer syndrome Diseases 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- MYHXHCUNDDAEOZ-UHFFFAOYSA-N Prostaglandin A&2% Natural products CCCCCC(O)C=CC1C=CC(=O)C1CC=CCCCC(O)=O MYHXHCUNDDAEOZ-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 101100190148 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PGA2 gene Proteins 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- MYHXHCUNDDAEOZ-FOSBLDSVSA-N prostaglandin A2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1C\C=C/CCCC(O)=O MYHXHCUNDDAEOZ-FOSBLDSVSA-N 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 108091005475 signaling receptors Proteins 0.000 description 2
- 102000035025 signaling receptors Human genes 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 241000714186 AKR (endogenous) murine leukemia virus Species 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108010078140 Cation Transport Proteins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008723 Chondrodystrophy Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101710088341 Dermatopontin Proteins 0.000 description 1
- 208000013558 Developmental Bone disease Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010030242 Fibrillin-2 Proteins 0.000 description 1
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 1
- 108090000378 Fibroblast growth factor 3 Proteins 0.000 description 1
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 1
- 102000010453 Folate receptor gamma Human genes 0.000 description 1
- 108050001933 Folate receptor gamma Proteins 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 201000006813 Fukuyama congenital muscular dystrophy Diseases 0.000 description 1
- 101150027051 HO1 gene Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 1
- 101000999311 Homo sapiens Immunoglobulin superfamily member 8 Proteins 0.000 description 1
- 101001098872 Homo sapiens Proprotein convertase subtilisin/kexin type 7 Proteins 0.000 description 1
- 101001119115 Homo sapiens Ribosomal RNA-processing protein 8 Proteins 0.000 description 1
- 101000794187 Homo sapiens Tetraspanin-18 Proteins 0.000 description 1
- 101000800821 Homo sapiens Transforming growth factor beta receptor type 3 Proteins 0.000 description 1
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010041012 Integrin alpha4 Proteins 0.000 description 1
- 108010011301 Interleukin-12 Subunit p35 Proteins 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 208000009289 Jackson-Weiss syndrome Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 108010044023 Ki-1 Antigen Proteins 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 101000868474 Mus musculus Sialoadhesin Proteins 0.000 description 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 108010002519 Prolactin Receptors Proteins 0.000 description 1
- 102100038950 Proprotein convertase subtilisin/kexin type 7 Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102100026762 Ribosomal RNA-processing protein 8 Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101710083278 SLAM family member 6 Proteins 0.000 description 1
- 108091006647 SLC9A1 Proteins 0.000 description 1
- 108010082545 Secretory Leukocyte Peptidase Inhibitor Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108010074941 Sodium-Potassium-Chloride Symporters Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101000987219 Sus scrofa Pregnancy-associated glycoprotein 1 Proteins 0.000 description 1
- 108010010057 TYK2 Kinase Proteins 0.000 description 1
- 102100030175 Tetraspanin-18 Human genes 0.000 description 1
- 108700031126 Tetraspanins Proteins 0.000 description 1
- 102000043977 Tetraspanins Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 101710095163 Urotensin-2 Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 201000006793 Walker-Warburg syndrome Diseases 0.000 description 1
- 108050007995 Xylosyltransferase 1 Proteins 0.000 description 1
- 208000008919 achondroplasia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 108010028930 invariant chain Proteins 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 108010029560 keratinocyte growth factor receptor Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 102000037831 nucleoside transporters Human genes 0.000 description 1
- 108091006527 nucleoside transporters Proteins 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000010469 pro-virus integration Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- PVGBHEUCHKGFQP-UHFFFAOYSA-N sodium;n-[5-amino-2-(4-aminophenyl)sulfonylphenyl]sulfonylacetamide Chemical compound [Na+].CC(=O)NS(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 PVGBHEUCHKGFQP-UHFFFAOYSA-N 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66986105P | 2005-04-07 | 2005-04-07 | |
| PCT/US2006/013153 WO2006110581A2 (en) | 2005-04-07 | 2006-04-07 | Cancer-related genes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008535853A true JP2008535853A (ja) | 2008-09-04 |
| JP2008535853A5 JP2008535853A5 (enExample) | 2009-02-26 |
Family
ID=36809257
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505600A Pending JP2008535853A (ja) | 2005-04-07 | 2006-04-07 | 癌関連遺伝子 |
| JP2008505603A Pending JP2008535494A (ja) | 2005-04-07 | 2006-04-07 | 癌関連遺伝子（ｐｒｌｒ） |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505603A Pending JP2008535494A (ja) | 2005-04-07 | 2006-04-07 | 癌関連遺伝子（ｐｒｌｒ） |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090220495A1 (enExample) |
| EP (3) | EP1871911A2 (enExample) |
| JP (2) | JP2008535853A (enExample) |
| AU (1) | AU2006235258A1 (enExample) |
| CA (1) | CA2604844A1 (enExample) |
| WO (2) | WO2006110581A2 (enExample) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013168644A1 (ja) * | 2012-05-11 | 2013-11-14 | 独立行政法人国立がん研究センター | 腎細胞癌の予後予測方法 |
| JP2015008686A (ja) * | 2013-06-28 | 2015-01-19 | 三菱レイヨン株式会社 | 肝臓細胞又はその前駆細胞に由来する細胞の状態を評価する方法、並びに、その方法に用いるプローブ又はプローブセット及びマイクロアレイ |
| KR20150127611A (ko) * | 2013-03-11 | 2015-11-17 | 노파르티스 아게 | Wnt 억제제와 연관된 마커 |
| US9567641B2 (en) | 2013-07-03 | 2017-02-14 | Samsung Electronics Co., Ltd. | Combination therapy for the treatment of cancer using an anti-C-met antibody |
| WO2020197304A1 (ko) * | 2019-03-28 | 2020-10-01 | 황정후 | 테트라스파닌-2 억제제를 유효성분으로 포함하는 췌장암 예방, 개선 또는 치료용 조성물 |
| KR102169901B1 (ko) * | 2019-05-17 | 2020-10-26 | 연세대학교 산학협력단 | Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| JP7133159B1 (ja) | 2022-02-17 | 2022-09-08 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | ＴＧＦｂ ＲＩＩＩタンパク質の胃癌血清バイオマーカーとしての使用方法 |
| CN115551549A (zh) * | 2019-12-25 | 2022-12-30 | 上海寻百会生物科技有限公司 | 用于通过靶向igsf8来治疗自身免疫疾病和癌症的组合物和方法 |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| CA2555185C (en) | 2004-02-06 | 2020-03-24 | Morphosys Ag | Anti-cd38 human antibodies and uses therefor |
| JP5362359B2 (ja) | 2005-10-12 | 2013-12-11 | モルフォシス アーゲー | ヒトＣＤ３８に特異的な完全ヒトＨｕＣＡＬＧＯＬＤ由来の治療抗体の生成とプロファイリング |
| KR20090003178A (ko) | 2006-01-11 | 2009-01-09 | 게노믹 헬쓰, 인코포레이티드 | 직장결장암 예후에 대한 유전자 발현 마커 |
| JP2009536834A (ja) | 2006-05-12 | 2009-10-22 | ジェネンテック・インコーポレーテッド | 癌の診断及び治療のための方法及び組成物 |
| US20100021424A1 (en) * | 2006-06-02 | 2010-01-28 | Vincent Brichard | Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy |
| PL2032166T3 (pl) | 2006-06-13 | 2013-09-30 | Oncomed Pharm Inc | Kompozycje i sposoby diagnozowania i leczenia nowotworów |
| EP3018144A1 (en) * | 2006-08-18 | 2016-05-11 | XOMA Technology Ltd. | Prlr-specific antibody and uses thereof |
| JP5618544B2 (ja) | 2007-01-24 | 2014-11-05 | オンコメッドファーマシューティカルズ インコーポレイテッド | 癌の診断および処置のための組成物および方法 |
| JP2010525301A (ja) * | 2007-03-23 | 2010-07-22 | ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート | 子宮内膜癌および前癌の診断、分類および治療の方法 |
| WO2008117067A2 (en) | 2007-03-27 | 2008-10-02 | Carl Arne Krister Borrebaeck | Protein signature/markers for the detection of adenocarcinoma |
| US20100240035A1 (en) * | 2007-06-01 | 2010-09-23 | The Regents Of The University Of California | Multigene prognostic assay for lung cancer |
| JP5931336B2 (ja) | 2007-07-02 | 2016-06-08 | オンコメッド ファーマシューティカルズ インコーポレイテッド | がんを処置および診断するための組成物および方法 |
| EP2227556B1 (en) * | 2007-11-19 | 2014-08-27 | Celera Corporation | Lung cancer markers and uses thereof |
| CA2718854A1 (en) * | 2008-03-20 | 2009-09-24 | Transmolecular, Inc. | Inhibition of angiogenesis |
| BRPI0912683A2 (pt) | 2008-05-15 | 2016-01-26 | Transmolecular Inc | tratamento de tumores metastáticos |
| WO2010002862A2 (en) | 2008-07-01 | 2010-01-07 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (fgfr3) binding proteins |
| US8834875B2 (en) | 2010-01-13 | 2014-09-16 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| CN102316897B (zh) | 2008-07-08 | 2014-11-05 | 昂考梅德药品有限公司 | Notch结合剂和拮抗剂及其应用方法 |
| EP3115063A3 (en) * | 2008-12-03 | 2017-04-19 | The John Hopkins University | Galectin-3 and annexin-a2 as immunological target |
| WO2010127322A1 (en) | 2009-05-01 | 2010-11-04 | Genomic Health Inc. | Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy |
| CN106995493B (zh) | 2010-02-04 | 2021-09-24 | 卫材公司 | 氯毒素多肽和结合物及其应用 |
| WO2011142858A2 (en) | 2010-05-11 | 2011-11-17 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates, and methods for their use |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3431485B2 (en) | 2010-10-01 | 2024-09-04 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| GB201103726D0 (en) | 2011-03-04 | 2011-04-20 | Immunovia Ab | Method, array and use thereof |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| WO2012136519A1 (en) | 2011-04-06 | 2012-10-11 | Bayer Pharma Aktiengesellschaft | Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer |
| EP2530089A1 (en) | 2011-06-03 | 2012-12-05 | Bayer Pharma Aktiengesellschaft | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
| CN106167526A (zh) | 2011-07-15 | 2016-11-30 | 昂考梅德药品有限公司 | Rspo结合剂和其应用 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2013044164A1 (en) * | 2011-09-21 | 2013-03-28 | The Regents Of The University Of California | Methods to treat and/or prevent relapse in notch1-driven malignancies |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| EP2812350B1 (en) * | 2012-02-11 | 2019-04-03 | F.Hoffmann-La Roche Ag | R-spondin translocations and methods using the same |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| WO2013166153A2 (en) * | 2012-05-01 | 2013-11-07 | Brentnall Teri | Methods and compositions for cancer diagnosis |
| CA2878868A1 (en) | 2012-07-13 | 2014-01-16 | Austin L. Gurney | Rspo3 binding agents and uses thereof |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US20140179560A1 (en) | 2012-12-10 | 2014-06-26 | Fred Hutchinson Cancer Research Center | Drug discovery methods and platforms |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10323285B2 (en) | 2013-09-09 | 2019-06-18 | Nantomics, Llc | Proteomics analysis and discovery through DNA and RNA sequencing, systems and methods |
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
| GB201319878D0 (en) * | 2013-11-11 | 2013-12-25 | Immunovia Ab | Method, Array and use thereof |
| EP3091999B2 (en) | 2014-01-09 | 2025-05-07 | Hadasit Medical Research Services and Development Ltd. | Improved cell compositions and methods for cancer therapy |
| US9994912B2 (en) | 2014-07-03 | 2018-06-12 | Abbott Molecular Inc. | Materials and methods for assessing progression of prostate cancer |
| EP3193935A4 (en) | 2014-09-16 | 2018-03-21 | Oncomed Pharmaceuticals, Inc. | Treatment of fibrotic diseases |
| US12150980B2 (en) | 2015-07-30 | 2024-11-26 | Modernatx, Inc. | Concatemeric peptide epitope RNAs |
| US12048732B2 (en) | 2016-04-15 | 2024-07-30 | Blaze Bioscience, Inc. | Methods of treating breast cancer |
| JP2020529870A (ja) | 2017-08-10 | 2020-10-15 | ザ インスティチュート オブ キャンサー リサーチ，ロイヤル キャンサー ホスピタル | がんを層別化し、処置するための材料及び方法 |
| WO2019112489A1 (en) * | 2017-12-05 | 2019-06-13 | Limited Liability Company "Gero" | Methods and agents for treatment of aging and aging related conditions and diseases |
| WO2019155474A1 (en) | 2018-02-12 | 2019-08-15 | Hadasit Medical Research Services & Development Ltd. | Modulation of slamf6 splice variants for cancer therapy |
| KR101890392B1 (ko) * | 2018-05-28 | 2018-08-21 | 의료법인 성광의료재단 | Ｗｎｔ３ａ를 포함하는 난소암의 진단을 위한 마커 및 조성물 |
| US20220326243A1 (en) * | 2019-05-21 | 2022-10-13 | Acurasysbio Co., Ltd. | Composition for cancer diagnosis |
| IL267614A (en) * | 2019-06-24 | 2019-09-26 | Lotem Michal | Nucleic acids to modulate SLAMF6 isoforms |
| GB202010970D0 (en) | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004042028A2 (en) * | 2002-11-01 | 2004-05-21 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
| WO2005005601A2 (en) * | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
Family Cites Families (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
| US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
| US4956453A (en) | 1985-12-06 | 1990-09-11 | Cetus Corporation | Anti-human ovarian cancer immunotoxins and methods of use thereof |
| US4868105A (en) | 1985-12-11 | 1989-09-19 | Chiron Corporation | Solution phase nucleic acid sandwich assay |
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5359100A (en) | 1987-10-15 | 1994-10-25 | Chiron Corporation | Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers |
| US5124246A (en) | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
| US5206152A (en) | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0454781B1 (en) | 1989-01-23 | 1998-12-16 | Chiron Corporation | Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof |
| CA2049028A1 (en) | 1989-03-07 | 1990-09-08 | Genentech, Inc. | Covalent conjugates of lipid and oligonucleotide |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| DE69034168T3 (de) | 1989-03-21 | 2013-04-11 | Vical, Inc. | Expression von exogenen Polynukleotidsequenzen in Wirbeltieren |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| EP1645635A3 (en) | 1989-08-18 | 2010-07-07 | Oxford Biomedica (UK) Limited | Replication defective recombinant retroviruses expressing a palliative |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| WO1991004753A1 (en) | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
| US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
| US5149655A (en) | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
| RU2142467C1 (ru) | 1990-07-27 | 1999-12-10 | Чирон Диагностикс Корпорейшн | Полинуклеотиды, способ их получения, гибридизационный анализ нуклеиновой кислоты |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| JP3337214B2 (ja) | 1990-12-20 | 2002-10-21 | アーチ・ディベロップメント・コーポレーション | 電離線による遺伝子発現の調節 |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5419966A (en) | 1991-06-10 | 1995-05-30 | Microprobe Corporation | Solid support for synthesis of 3'-tailed oligonucleotides |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| WO1993014778A1 (en) | 1992-01-23 | 1993-08-05 | Vical, Inc. | Ex vivo gene transfer |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| WO1993022443A1 (en) | 1992-04-24 | 1993-11-11 | Sri International | In vivo homologous sequence targeting in eukaryotic cells |
| JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
| JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
| WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
| AU6818094A (en) | 1993-04-22 | 1994-11-08 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
| JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル． グラハム，フランク | 遺伝子治療のためのアデノウイルスベクター |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| EP0694070B1 (en) | 1993-09-15 | 2002-04-10 | Chiron Corporation | Recombinant alphavirus vectors |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| JP3875990B2 (ja) | 1993-10-25 | 2007-01-31 | カンジ，インコーポレイテッド | 組換えアデノウイルスベクターおよび使用方法 |
| NZ276305A (en) | 1993-11-16 | 1997-10-24 | Depotech Corp | Controlled release vesicle compositions |
| US5681697A (en) | 1993-12-08 | 1997-10-28 | Chiron Corporation | Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor |
| US6015880A (en) | 1994-03-16 | 2000-01-18 | California Institute Of Technology | Method and substrate for performing multiple sequential reactions on a matrix |
| WO1995030763A2 (en) | 1994-05-09 | 1995-11-16 | Chiron Viagene, Inc. | Retroviral vectors having a reduced recombination rate |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
| US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
| US5681702A (en) | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| EP1295952A3 (en) | 1996-01-23 | 2003-07-09 | The Board of Trustees of The Leland Stanford Junior University | Methods for screening for transdominant effector peptides and RNA molecules |
| AU2998597A (en) | 1996-05-06 | 1997-11-26 | Chiron Corporation | Crossless retroviral vectors |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| US6475220B1 (en) | 1999-10-15 | 2002-11-05 | Whiteside Biomechanics, Inc. | Spinal cable system |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US6406840B1 (en) | 1999-12-17 | 2002-06-18 | Biomosaic Systems, Inc. | Cell arrays and the uses thereof |
| DE10019058A1 (de) * | 2000-04-06 | 2001-12-20 | Epigenomics Ag | Detektion von Variationen des DNA-Methylierungsprofils |
| WO2002050098A2 (en) * | 2000-12-18 | 2002-06-27 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the prlr gene |
| US7645441B2 (en) * | 2000-12-22 | 2010-01-12 | Sagres Discovery Inc. | Compositions and methods in cancer associated with altered expression of PRLR |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2003008583A2 (en) * | 2001-03-02 | 2003-01-30 | Sagres Discovery | Novel compositions and methods for cancer |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US7705120B2 (en) * | 2001-06-21 | 2010-04-27 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| US7074175B2 (en) | 2001-07-25 | 2006-07-11 | Erik Schroeder Handy | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| US6997863B2 (en) | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| EP1466016A2 (en) * | 2002-01-09 | 2004-10-13 | Riken Institute Of Physical And Chemical Research | Cancer profiles |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| EP2233572A3 (en) * | 2002-06-06 | 2011-01-12 | Oncotherapy Science, Inc. | Genes and polypeptides relating to human colon cancers |
| WO2004016317A1 (en) * | 2002-08-14 | 2004-02-26 | Erasmus University Medical Center Rotterdam | Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer |
| PL1651162T3 (pl) | 2003-05-20 | 2016-04-29 | Immunogen Inc | Maitansynoidy w leczeniu nowotworów |
| WO2004105573A2 (en) * | 2003-05-21 | 2004-12-09 | The Wistar Institute Of Anatomy And Biology | Method of diagnosis of cancer based on gene expression profiles in cells |
| CA2527321A1 (en) * | 2003-05-30 | 2004-12-23 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| JP2006526998A (ja) * | 2003-06-12 | 2006-11-30 | コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー | 胃癌および転移性胃癌診断キット |
| DK1639011T3 (da) | 2003-06-30 | 2009-02-16 | Domantis Ltd | Pegylerede enkelt-domæne antistoffer (dAb) |
| JP2005073548A (ja) * | 2003-08-29 | 2005-03-24 | National Cancer Center-Japan | 卵巣明細胞腺癌の検査、治療、および治療薬のスクリーニングのための、ＨＮＦ−１βの利用 |
| JP2007506425A (ja) * | 2003-09-24 | 2007-03-22 | オンコセラピー・サイエンス株式会社 | 肝細胞癌を診断する方法 |
| WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| EP1805519B1 (en) * | 2004-09-21 | 2013-11-06 | Rhode Island Hospital | Wnt proteins and detection and treatment of cancer |
-
2006
- 2006-04-07 JP JP2008505600A patent/JP2008535853A/ja active Pending
- 2006-04-07 JP JP2008505603A patent/JP2008535494A/ja active Pending
- 2006-04-07 CA CA002604844A patent/CA2604844A1/en not_active Abandoned
- 2006-04-07 EP EP06749567A patent/EP1871911A2/en not_active Ceased
- 2006-04-07 EP EP09001181A patent/EP2083088A3/en not_active Withdrawn
- 2006-04-07 WO PCT/US2006/013153 patent/WO2006110581A2/en not_active Ceased
- 2006-04-07 US US11/910,837 patent/US20090220495A1/en not_active Abandoned
- 2006-04-07 AU AU2006235258A patent/AU2006235258A1/en not_active Abandoned
- 2006-04-07 WO PCT/US2006/013160 patent/WO2006110585A2/en not_active Ceased
- 2006-04-07 EP EP06749562A patent/EP1910557A2/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004042028A2 (en) * | 2002-11-01 | 2004-05-21 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
| WO2005005601A2 (en) * | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018139600A (ja) * | 2012-05-11 | 2018-09-13 | 国立研究開発法人国立がん研究センター | 腎細胞癌の予後予測方法 |
| WO2013168644A1 (ja) * | 2012-05-11 | 2013-11-14 | 独立行政法人国立がん研究センター | 腎細胞癌の予後予測方法 |
| JP2018148900A (ja) * | 2012-05-11 | 2018-09-27 | 国立研究開発法人国立がん研究センター | 腎細胞癌の予後予測方法 |
| JPWO2013168644A1 (ja) * | 2012-05-11 | 2016-01-07 | 国立研究開発法人国立がん研究センター | 腎細胞癌の予後予測方法 |
| JP2018139601A (ja) * | 2012-05-11 | 2018-09-13 | 国立研究開発法人国立がん研究センター | 腎細胞癌の予後予測方法 |
| JP2018139599A (ja) * | 2012-05-11 | 2018-09-13 | 国立研究開発法人国立がん研究センター | 腎細胞癌の予後予測方法 |
| KR102194746B1 (ko) | 2013-03-11 | 2020-12-24 | 노파르티스 아게 | Wnt 억제제와 연관된 마커 |
| KR20150127611A (ko) * | 2013-03-11 | 2015-11-17 | 노파르티스 아게 | Wnt 억제제와 연관된 마커 |
| JP2015008686A (ja) * | 2013-06-28 | 2015-01-19 | 三菱レイヨン株式会社 | 肝臓細胞又はその前駆細胞に由来する細胞の状態を評価する方法、並びに、その方法に用いるプローブ又はプローブセット及びマイクロアレイ |
| US9567641B2 (en) | 2013-07-03 | 2017-02-14 | Samsung Electronics Co., Ltd. | Combination therapy for the treatment of cancer using an anti-C-met antibody |
| WO2020197304A1 (ko) * | 2019-03-28 | 2020-10-01 | 황정후 | 테트라스파닌-2 억제제를 유효성분으로 포함하는 췌장암 예방, 개선 또는 치료용 조성물 |
| KR102169901B1 (ko) * | 2019-05-17 | 2020-10-26 | 연세대학교 산학협력단 | Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| WO2020235827A1 (ko) * | 2019-05-17 | 2020-11-26 | 연세대학교 산학협력단 | 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| CN115551549A (zh) * | 2019-12-25 | 2022-12-30 | 上海寻百会生物科技有限公司 | 用于通过靶向igsf8来治疗自身免疫疾病和癌症的组合物和方法 |
| JP2023512151A (ja) * | 2019-12-25 | 2023-03-24 | シャンハイ・エックスビーエイチ・バイオテクノロジー・カンパニー・リミテッド | Ｉｇｓｆ８を標的化することによる自己免疫疾患および癌を治療するための組成物および方法 |
| JP7133159B1 (ja) | 2022-02-17 | 2022-09-08 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | ＴＧＦｂ ＲＩＩＩタンパク質の胃癌血清バイオマーカーとしての使用方法 |
| JP2023120118A (ja) * | 2022-02-17 | 2023-08-29 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | ＴＧＦｂ ＲＩＩＩタンパク質の胃癌血清バイオマーカーとしての使用方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2083088A3 (en) | 2009-10-14 |
| EP2083088A2 (en) | 2009-07-29 |
| AU2006235258A1 (en) | 2006-10-19 |
| US20090220495A1 (en) | 2009-09-03 |
| CA2604844A1 (en) | 2006-10-19 |
| WO2006110585A3 (en) | 2006-12-21 |
| WO2006110581A2 (en) | 2006-10-19 |
| EP1910557A2 (en) | 2008-04-16 |
| JP2008535494A (ja) | 2008-09-04 |
| EP1871911A2 (en) | 2008-01-02 |
| WO2006110581A3 (en) | 2007-07-12 |
| WO2006110585A2 (en) | 2006-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008535853A (ja) | 癌関連遺伝子 | |
| US20070237770A1 (en) | Novel compositions and methods in cancer | |
| EP2062591A1 (en) | CACNA1E in cancer diagnosis detection and treatment | |
| AU2004276821A1 (en) | Novel therapeutic targets in cancer | |
| US7919246B2 (en) | SEMA4D in cancer diagnosis, detection and treatment | |
| US20070098728A1 (en) | Novel compositions and methods in cancer | |
| JP4942219B2 (ja) | 癌の診断、検出および処置におけるｄｄｒ２ | |
| US20090297507A1 (en) | ADAM10 in Cancer Diagnosis, Detection and Treatment | |
| AU2005240070A1 (en) | Novel compositions and methods in cancer | |
| AU2003299897B2 (en) | Novel compositions and methods in cancer | |
| US20090317391A1 (en) | Cancer Related Genes (PTPE) | |
| JP2008507281A (ja) | 癌における新規の治療標的 | |
| AU2005262348A1 (en) | Novel compositions and methods in cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090106 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090106 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110819 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111118 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111128 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120712 |